cas 2864383-31-1|| where to buy Lithium(2R,3R)-3-cyclopropyl-1-methylaziridine-2-carboxylate

Produktname:Lithium(2R,3R)-3-cyclopropyl-1-methylaziridine-2-carboxylate

IUPAC Name:(2R,3R)-3-cyclopropyl-1-methylaziridine-2-carboxylic acid lithium

Packungseinheit	Verfügbarer Vorrat	Preis($)	Menge

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2864383-31-1 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:2864383-31-1; Molekulare Formel:C7H11LiNO2; Schmelzpunkt:-; SMILES-Code:C(O)(=O)[C@H]1[C@H](N1C)C2CC2.[Li]; Dichte:

: Katalognummer:CM1048983; Molekulargewicht:148.11; Siedepunkt:; Mdl-Nr.:; Lagerung:

: Aziridines; Aziridines are highly strained three-membered heterocyclic molecules composed of one amine group and two carbon units. They are aza analogs of epoxides. Aziridines are a very important class of synthetic building blocks and intermediates in organic synthesis, which are widely used in organic synthesis, especially in the synthesis of nitrogen-containing natural products. Due to the high ring tension of aziridine, its reactivity is high. Under certain conditions, it can undergo cycloaddition reaction with various dipolar reagents to prepare some new nitrogen-containing heterocyclic compounds.; Aziridines are a very important class of synthetic building blocks and intermediates in organic synthesis; Aziridines,; Aziridines are highly strained three-membered heterocyclic molecules composed of one amine group and two carbon units. They are aza analogs of epoxides.

: RMC-9805; Revolution Medicines announced preliminary positive data for its RAS(ON) G12D-selective covalent inhibitor RMC-9805 in previously treated pancreatic ductal adenocarcinoma (PDAC) patients. The analysis showed that the disease control rate of PDAC patients treated with RMC-9805 was as high as 80%. RMC-9805 is a potential ‘first-in-class’ oral RAS(ON) G12D-selective inhibitor, that is being evaluated in trials to examine its efficacy and safety in patients with solid tumors carrying KRAS G12D mutations when used as a single agent or in combination with the pan-RAS inhibitor RMC-6236.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.